Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC

Phase 2

Not yet recruiting

Conditions: Advanced HCC

Interventions: Drug: Lenalidomide

First Posted Date: 2023-04-26

Last Posted Date: 2023-04-26

Lead Sponsor: Shenyang Tenth People's Hospital

Target Recruit Count: 23

Registration Number: NCT05831969

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Lenalidomide

First Posted Date: 2023-04-24

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1216

Registration Number: NCT05827016

Locations: 🇫🇷
CHU Hôpital Sud, Amiens Cedex 1, France
🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

and more 264 locations

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Grade 3b Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Drug: Ifosfamide
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Biological: Tafasitamab

First Posted Date: 2023-04-20

Last Posted Date: 2024-11-15

Lead Sponsor: David Bond, MD

Target Recruit Count: 37

Registration Number: NCT05821088

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2

Withdrawn

Conditions: Multiple Myeloma
Myeloma-Associated Amyloidosis

Interventions: Drug: Selinexor
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2023-04-20

Last Posted Date: 2024-07-10

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT05820763

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-04-07

Last Posted Date: 2024-05-29

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 514

Registration Number: NCT05804032

Locations: 🇦🇹
Phyrn-Eisenwurzen Klinikum Steyr, Steyr, Austria
🇦🇹
Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz, Salzburg, Austria
🇩🇪
Charité, III. Medizinische Abteilung (Hämatologie/Onkologie), Berlin, Germany

and more 78 locations

The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Colchicine
Drug: Lenalidomide

First Posted Date: 2023-04-07

Last Posted Date: 2023-04-07

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 30

Registration Number: NCT05802992

Locations: 🇨🇳
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Not Applicable

Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Zanubrutinib
Drug: Lenalidomide
Drug: CD19/CD22 CAR-T
Drug: Azacitidine For Injection
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-04-04

Last Posted Date: 2023-04-04

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 20

Registration Number: NCT05797948

Locations: 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 2

Terminated

Conditions: Mantle Cell Lymphoma
MCL

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2023-03-28

Last Posted Date: 2024-08-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT05788289

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States

and more 4 locations

Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: lenalidomide

First Posted Date: 2023-03-20

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT05776979

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Teclistamab (Tec)
Drug: Lenalidomide
Drug: Talquetamab
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2023-01-25

Last Posted Date: 2024-10-23

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 130

Registration Number: NCT05695508

Locations: 🇩🇪
Charité University Medicin Berlin, Berlin, Germany
🇩🇪
Clinic Chemnitz gGmbH, Chemnitz, Germany
🇩🇪
University Clinic Technical University Dresden, Dresden, Germany

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy